News

Researchers find that a specially formulated antioxidant-enriched supplement may decrease respiratory illnesses in patients with cystic fibrosis.

Individualized holistic, evidence-based medicine will be accessible to more patients in New York beginning in June 2018, when the 2-year-old Integrative Health and Wellbeing program expands from its original site.

The most recent approval in the class, ertugliflozin (Steglatro), is a product of the efforts of a duo of pharmaceutical giants, Pfizer and Merck.

The new findings also show that the premature activation of synapses can be prevented by AMPA receptor antagonist therapy.

These are the first FDA Premarket Approved stents for stent-assisted coil embolization.

The US FDA has granted Genea Biocells Orphan Drug Designation to its product, GBC0905, for the treatment of facioscapulohumeral muscular dystrophy (FSHD).

FDA Commissioner Scott Gottlieb addressed the back-end tactics employed by pharmaceutical companies to delay the entry of a generic drug into the market.

Upon unearthing rheumatoid arthritis’ epigenome, researchers at University of California San Diego School of Medicine and the Icahn School of Medicine at Mount Sinai have also discovered an overlap between the causes of rheumatoid arthritis and Huntington’s disease.

Whether comprised of a nurse anesthetist or anesthesiologist assistant, patients undergoing surgery experienced no significant differences in mortality, length of stay, or inpatient costs.

The CustomFlex Artificial Iris is customizable by both size and eye color, and indicated for both adults and children.

The FDA approved the first artificial iris for both pediatric and adult patients with aniridia who have an iris that is completely missing or damaged.

The NeuralBot assists clinicians in non-invasive monitor of patient brain blood flow characteristics, and provides diagnostic information for a variety of neurological disorders.

Marijke van den Berg, MD, PhD, Alok Srivastava, MD, and Glenn Pierce, MD, PhD discuss gene therapy in hemophilia.

Tofacitinib was evaluated for the expansion of its indication based on data from 3 clinical trials.

The investigative monoclonal antibody has more data backing its efficacy, safety, and tolerability across 2 dose regimens.

The supplemental New Drug Application for perampanel (Fycompa) expands the indication to include pediatric patients 2-12 years of age.

In an exclusive interview, Cary O. Harding, MD, provides Rare Disease Report® with insight into pegvaliase-pqpz and its recent approval by the FDA to treat patients with PKU.

The solution from Sage Therapeutics may become the first treatment indicated for women with postpartum depression.

The cap is the first and only device that kills infection-causing bacteria inside a long-term catheter, preventing contamination.

The FDA has accepted its supplemental New Drug Application (sNDA) and granted Priority Review designation to Promacta (eltrombopag) in combination with standard immunosuppressive therapy (IST) for first-line treatment of severe aplastic anemia (SAA).

Submissions can include products in any stage of development and will be accepted from June 1 to September 30, 2018. The selections will be announced in November.

IMVEXXY is the only product in its therapeutic class to offer a 4 mcg and 10 mcg dose.

Eltrombopag (Promacta) was granted Priority Review designation, indicating a 6-month timeline for review.

Poison Control Centers get roughly 200 calls each week related to children and adolescents under the age of 19 being exposed to medications intended for attention-deficit hyperactivity disorder.

The NDA for the investigative long-acting subcutaneous buprenorphine injection was turned down in lieu of more data in January.

The zEEG provides clinicians and patients with an EEG system that is simple, easy and convenient that benefits with a quick and smart analysis of data through a cloud platform.

The US FDA has granted Astellas Pharma Inc priority review for gilteritinib for refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.

Specifically, the first 4 days of the capsules were packaged with 4 non-hormonal placebo capsules in place of their active counterparts.

The T2Bacterial Panel has proven able to detect specific sepsis-causing bacterial pathogens nearly 10 times faster than competitors.

The Nipah virus outbreak in India's southern state of Kerala may have spread to the neighboring state of Karnataka.